| 33.53 -0.31 (-0.92%) | 08-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.37 | 1-year : | 47.15 |
| Resists | First : | 34.56 | Second : | 40.37 |
| Pivot price | 28.67 |
|||
| Supports | First : | 28.34 | Second : | 24.5 |
| MAs | MA(5) : | 32.49 |
MA(20) : | 27.91 |
| MA(100) : | 27.32 |
MA(250) : | 28.51 |
|
| MACD | MACD : | 1.7 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 89.8 |
D(3) : | 84.5 |
| RSI | RSI(14): 68.1 |
|||
| 52-week | High : | 39.7 | Low : | 20.22 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ASMB ] has closed below upper band by 9.4%. Bollinger Bands are 125.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 34.04 - 34.22 | 34.22 - 34.37 |
| Low: | 32.48 - 32.68 | 32.68 - 32.85 |
| Close: | 33.2 - 33.54 | 33.54 - 33.84 |
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Wed, 19 Aug 2026
Assembly Biosciences (NASDAQ:ASMB) Shares Gap Up - Should You Buy? - MarketBeat
Tue, 18 Aug 2026
Assembly Biosciences (ASMB) Slides 8.92% to $30.01 as Key Support Comes into Focus - Fundamental Weighted - Vinanet
Tue, 18 Aug 2026
Assembly Biosciences (NASDAQ:ASMB) Earns "Buy" Rating from HC Wainwright - MarketBeat
Sun, 16 Aug 2026
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal - Seeking Alpha
Fri, 14 Aug 2026
Assembly Biosciences (ASMB) sees Paradigm BioCapital report 7.8% ownership stake - Stock Titan
Fri, 14 Aug 2026
Assembly Biosciences, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ASMB | US0453962070 - marketscreener.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 28.4 (%) |
| Held by Institutions | 55.2 (%) |
| Shares Short | 2,310 (K) |
| Shares Short P.Month | 1,870 (K) |
| EPS | 0.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.5 |
| Profit Margin | -9 % |
| Operating Margin | -138.5 % |
| Return on Assets (ttm) | -5.1 % |
| Return on Equity (ttm) | -5.7 % |
| Qtrly Rev. Growth | -12.9 % |
| Gross Profit (p.s.) | 0.31 |
| Sales Per Share | 3.58 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -40 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | 419.12 |
| PEG Ratio | 0 |
| Price to Book value | 2.68 |
| Price to Sales | 9.34 |
| Price to Cash Flow | -16.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|